Arabic Arabic English English French French German German
dark

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

SQZ Biotechnologies today announced that the first clinical translation of the company’s Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Next Post

Children of cancer patients are too often excluded from the disease journey, research shows

Related Posts
Total
0
Share